Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned an average rating of “Moderate Buy” from the eighteen brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $59.8824.

Several equities research analysts recently issued reports on RARE shares. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Wells Fargo & Company raised their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Wall Street Zen cut Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Guggenheim cut their target price on Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Barclays reduced their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th.

Ultragenyx Pharmaceutical Stock Down 1.3%

Shares of Ultragenyx Pharmaceutical stock opened at $23.39 on Friday. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -3.83 and a beta of 0.39. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $42.37. The company has a 50-day simple moving average of $23.22 and a two-hundred day simple moving average of $26.12.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. During the same quarter in the previous year, the company earned ($1.57) EPS. The business’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -4.62 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 8,135 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $185,478.00. Following the sale, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This represents a 9.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director directly owned 27,951 shares in the company, valued at approximately $702,129.12. This trade represents a 17.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 117,262 shares of company stock worth $2,687,403 in the last quarter. 5.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 29,984 shares in the last quarter. Creative Planning acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $454,000. American Century Companies Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $366,000. M&T Bank Corp grew its holdings in shares of Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 1,192 shares in the last quarter. Finally, Amundi grew its holdings in shares of Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after purchasing an additional 93,189 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.